Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 1/20 | 0.40 |
| ▸ | ATP4B | P51164 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22688325 | 0.88 | ALOX15 (0.48) | CYP3A4CYP2D6CYP2C19TP53THRB | |
| SCHEMBL27902741 | 0.85 | CYP3A4 (0.48) | CYP3A4CYP2D6TSHRCYP2C19TP53 | |
| SCHEMBL810597 | 0.85 | HDAC6 (0.47) | CYP3A4CYP2D6TSHRCYP2C19TP53 | |
| SCHEMBL12463289 | 0.83 | ALOX15 (0.56) | CYP3A4TSHRTP53THRBALOX15 | |
| SCHEMBL4442750 | 0.82 | BCL2 (0.54) | CYP3A4CYP2D6TSHRCYP2C19ALOX15 | |
| SCHEMBL29454271 | 0.81 | BCL2 (0.44) | CYP3A4CYP2D6TSHRCYP2C19HDAC6 | |
| SCHEMBL22232131 | 0.81 | BCL2 (0.44) | CYP3A4CYP2D6TSHRCYP2C19HDAC6 | |
| SCHEMBL9172065 | 0.80 | HDAC6 (0.55) | SMN1; SMN2TDP1HDAC6HTR2ANPC1 | |
| Ammonia Solution, Strong SCHEMBL2494070 | 0.80 | MAPT (0.47) | CYP3A4TP53THRBALOX15SMN1; SMN2 | |
| SCHEMBL6839208 | 0.80 | HTR2A (0.48) | CYP3A4TSHRTDP1BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115243764-B | Heterocyclic derivatives as TRMP antagonists | 奇华顿股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230098332-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | GIVAUDAN SA (CH) | 2023-03-30 | — | — | US | disclosed |
| EP-4114523-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Givaudan SA (CH) | 2023-01-11 | — | — | EP | disclosed |
| CN-115243764-A | Heterocyclic derivatives as TRMP8 antagonists | 奇华顿股份有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2018049296-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2016113757-A1 | NOVEL RECYCLABLE IODINATING AGENT AND ITS APPLICATIONS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-21 | — | — | WO | disclosed |
| EP-0301549-B1 | 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1992-10-28 | — | — | EP | disclosed |
| US-4859675-A | 1-[2-(phenylmethyl) phenyl]piperazines as antidepressants | FERRER INTERNACIONAL S.A. (ES) | 1989-08-22 | — | — | US | disclosed |
| EP-0301549-A1 | 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098332-A1 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | CYP3A4 1202/4885CYP2D6 1109/4885TSHR 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.